GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Additional Paid-In Capital

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Additional Paid-In Capital : $23.34 Mil(As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Additional Paid-In Capital?


Telomir Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2023 ($6.92 Mil) to Dec. 2023 ($17.50 Mil) and increased from Dec. 2023 ($17.50 Mil) to Mar. 2024 ($23.34 Mil).

Telomir Pharmaceuticals's annual additional paid-in capital stayed the same from Dec. 2021 ($0.06 Mil) to Dec. 2022 ($0.06 Mil) but then increased from Dec. 2022 ($0.06 Mil) to Dec. 2023 ($17.50 Mil).

Telomir Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Telomir Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Additional Paid-In Capital Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
0.06 0.06 17.50

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only - 6.92 6.92 17.50 23.34

Telomir Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Telomir Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Additional Paid-In Capital
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines

From GuruFocus

UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

By GlobeNewswire • 03-29-2024